Skip to content

Influence of Piperine on the bioavailability of epicatechin and epigallocatechin - a pilot study

Influence of Piperine on the bioavailability of epicatechin and epigallocatechin - a pilot study - E-Pip-Pilot

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00020741
Enrollment
6
Registered
2020-02-18
Start date
2021-04-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioavailability of epigallocatechin gallate and epicatechin

Interventions

Group 1: Epigallocatechin gallate, 50 mg p.o. capsule, once Group 2: Epigallocatechin gallate + Piperine, 50 mg + 20 mg p.o. capsule, once Group 3: Epicatechin, 50 mg p.o. capsule, once Group 4: Epica

Sponsors

Universität Bonn, Institut für Ernährungs- und Lebensmittelwissenschaften, Lebensmittelwissenschaft
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: - Age: 18-50 years - Normal weight, i.e. according to WHO (2004) BMI 18.5 - 24.9 kg/m2 - Written declaration of consent - Voluntary participation

Exclusion criteria

Exclusion criteria: - Smoking - Pregnancy (to be checked by pregnancy test or medical information; a pregnancy test will be provided) - Lactation - Frequent green tea consumption (more than three cups per week) - Frequent consumption of cocoa (corresponding to 50 g dark chocolate per day) - Known allergy to pepper or mugwort ("Celery-carrot-mugwort spice syndrome") - Known diseases and conditions affecting the bioavailability or metabolism and excretion of flavanols, e.g. malabsorption syndrome, diseases of the thyroid, kidneys and liver, coronary heart disease, diabetes mellitus, chronic inflammatory diseases - Regular intake of drugs that could have an influence on the target parameters - Taking food supplements (especially flavanol-containing ones such as cocoa and green tea extract, as well as caffeine) - Misuse of alcohol, medication and/or drugs (BTMG or other psychotropic substances) - Known infection with hepatitis B, hepatitis C or HIV - Limited legal capacity - Participation in another clinical study (current or in the past month) - Any other condition that, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
Concentration of EGCg and epicatechin as well as metabolites in blood plasma; measurement by HPLC-CEAD scheduled within one month after the last intervention.

Countries

Germany

Contacts

Public ContactBenno Zimmermann

Universität Bonn, Institut für Ernährungs- und Lebensmittelwissenschaften, Lebensmittelwissenschaft

benno.zimmermann@uni-bonn.de0228732016

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026